Author
Listed:
- Qingjian Li
(Sun Yat-Sen University)
- Tao Qin
(Sun Yat-Sen University)
- Zhuofei Bi
(Sun Yat-Sen University)
- Huangming Hong
(Sun Yat-Sen University)
- Lin Ding
(Sun Yat-Sen University)
- Jiewen Chen
(Sun Yat-Sen University)
- Wei Wu
(Sun Yat-Sen University
Sun Yat-Sen University)
- Xiaorong Lin
(Sun Yat-Sen University)
- Wenkui Fu
(Sun Yat-Sen University)
- Fang Zheng
(Sun Yat-Sen University)
- Yandan Yao
(Sun Yat-Sen University)
- Man-Li Luo
(Sun Yat-Sen University)
- Phei Er Saw
(Sun Yat-Sen University)
- Gerburg M. Wulf
(Harvard Medical School)
- Xiaoding Xu
(Sun Yat-Sen University)
- Erwei Song
(Sun Yat-Sen University
Sun Yat-Sen University)
- Herui Yao
(Sun Yat-Sen University
Sun Yat-Sen University)
- Hai Hu
(Sun Yat-Sen University
Sun Yat-Sen University)
Abstract
Resistance development to one chemotherapeutic reagent leads frequently to acquired tolerance to other compounds, limiting the therapeutic options for cancer treatment. Herein, we find that overexpression of Rac1 is associated with multi-drug resistance to the neoadjuvant chemotherapy (NAC). Mechanistically, Rac1 activates aldolase A and ERK signaling which up-regulates glycolysis and especially the non-oxidative pentose phosphate pathway (PPP). This leads to increased nucleotides metabolism which protects breast cancer cells from chemotherapeutic-induced DNA damage. To translate this finding, we develop endosomal pH-responsive nanoparticles (NPs) which deliver Rac1-targeting siRNA together with cisplatin and effectively reverses NAC-chemoresistance in PDXs from NAC-resistant breast cancer patients. Altogether, our findings demonstrate that targeting Rac1 is a potential strategy to overcome acquired chemoresistance in breast cancer.
Suggested Citation
Qingjian Li & Tao Qin & Zhuofei Bi & Huangming Hong & Lin Ding & Jiewen Chen & Wei Wu & Xiaorong Lin & Wenkui Fu & Fang Zheng & Yandan Yao & Man-Li Luo & Phei Er Saw & Gerburg M. Wulf & Xiaoding Xu & , 2020.
"Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer,"
Nature Communications, Nature, vol. 11(1), pages 1-18, December.
Handle:
RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-15308-7
DOI: 10.1038/s41467-020-15308-7
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-15308-7. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.